

a.) Amendments to the Specification

Please amend the paragraph at page 1, lines 15-16 to read as follows.

In accordance with the present invention, it there is provided a compound represented by the general formula (I);

Please amend the paragraph starting at page 7, line 10 and ending at page 8, line 1 to read as follows.

(wherein "p's" in individual amino acid residues are the same or different, and represent 0 or 1; Z<sup>1</sup> represents Ala, Phe or Pro; Z<sup>2</sup> represents Arg, Lys or Gln; Z<sup>3</sup>, Z<sup>15</sup> and Z<sup>21</sup> are the same or different, representing Gly or Pro; Z<sup>4</sup> represents Arg, Lys, Met or Pro; Z<sup>5</sup> represents Gly, Cys, Ala or Gln; Z<sup>6</sup> represents Ala, Arg or Glu; Z<sup>7</sup> represents Ala, Ile or Gln; Z<sup>8</sup> represents Ala, Gly or Arg; Z<sup>9</sup> represents Leu, Val or Pro; Z<sup>10</sup> represents Asp, Arg or Gln; Z<sup>11</sup> represents Gly, Ser, Ala or Pro; Z<sup>12</sup> represents Leu or Pro; Z<sup>13</sup> represents Asp, His or Pro; Z<sup>14</sup> represents Ser or Pro; Z<sup>16</sup> represents Gln or Lys; Z<sup>17</sup> represents Gly, Thr or Leu; Z<sup>18</sup> represents Gly, Pro or Val; Z<sup>19</sup> represents Gly or Lys; Z<sup>20</sup> represents Ala or Ser; Z<sup>22</sup> represents Gly or Ser; Z<sup>23</sup> represents Gly, Glu or Thr; Z<sup>24</sup> represents Arg, Lys, Ser or Pro; Z<sup>25</sup> represents Ser or Thr; Z<sup>27</sup> represents His or Tyr; Z<sup>28</sup> represents Asp or Glu; Z<sup>29</sup> and Z<sup>36</sup> are the same or different, representing Lys or Thr; Z<sup>32</sup> represents Gly or Asn; Z<sup>34</sup> represents Leu or Thr; Z<sup>37</sup> represents Arg or Lys; Z<sup>39</sup> represents Ile, Leu or Val; and Z<sup>40</sup> represents Glu, Gln, Ser or ~~Tyr~~ Tyr).

Please amend the paragraph at page 12, lines 11-19 to read as follows.

The pharmaceutically acceptable salt of the Compound (I) can be obtained in a conventional manner. More specifically, the acid addition salt or organic base addition salt of the Compound (I) can be ~~obtained~~ obtained by dissolving the Compound (I) in an aqueous solution of an acid or an organic base corresponding thereto and then

freeze-drying the solution. The metal salt of the Compound (I) can be obtained by dissolving the Compound (I) in an aqueous solution containing the corresponding metal ion and purifying the solution by gel filtration or by HPLC.

Please amend the paragraphs at page 31, lines 18-23 to read as follows.

#### Example 1

##### Synthesis of Compound Ia-1

(CH<sub>3</sub> -CO-Leu-Asn-Trp-Ala-Ala-Glu-Val-Leu-~~ty~~ Lys  
~~s~~-Val-Gln-Lys-Arg-Arg-Ile-Tyr-Asp-Ile-~~Th~~ Thr  
~~r~~-Asn-Val-Leu-Glu-Gly-Ile-Gln-Leu-Ile-~~Al~~ Ala  
α-NH<sub>2</sub>, SEQ ID No.1)

Please amend the paragraphs at page 34, lines 20-23 to read as follows.

#### Example 2

##### Synthesis of Compound Ia-2

(CH<sub>3</sub>-CO-Val-Leu-Lys-Val-Gln-Lys-Arg-Arg-~~Ile~~  
~~e~~-Tyr-Asp-Ile-Thr-Asn-Val-NH<sub>2</sub>, SEQ ID No.2)

Please amend the paragraph at page 35, lines 1-6 to read as follows.

Fmoc-Val-OH, Fmoc-Asn (Trt)-OH, Fmoc-Thr (~~t-~~ (t-Bu)  
~~Bu~~)-OH, Fmoc-Ile-OH, Fmoc-Asp (Ot-Bu)-OH, ~~Fm~~ Fmoc  
~~oc~~-Tyr (t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Arg (Pmc)  
-OH, Fmoc-Arg (Pmc)-OH, Fmoc-Lys (Boc)-OH, ~~Fm~~ Fmoc  
~~oc~~-Gln (Trt)-OH, Fmoc-Val-OH, Fmoc-Lys (Boc)  
-OH, Fmoc-Leu-OH, and Fmoc-Val-OH.

Please amend the paragraphs at starting at page 35, lines 23 and ending at page 36, line 3 to read as follows.

Example 3

Synthesis of Compound Ib-1

(CH<sub>3</sub>-CO-Asn-Glu-Ser-Ala-Tyr-Asp-Gln-Lys-~~As~~ Asn

n-Ile-Arg-Arg-Arg-Val-Tyr-Asp-Ala-Leu-~~As~~ Asn

n-Val-Leu-Met-Ala-Met-Asn-Ile-Ile-Ser-NH NH<sub>2</sub>.

~~27~~ SEQ ID No.3)

Please amend the paragraph at page 36, lines 7-17 to read as follows.

Fmoc-Ser (t-Bu)-OH, Fmoc-Ile-OH, ~~Fmoc-Ile-O~~ Fmoc-Ile-OH,

~~H~~, Fmoc-Asn (Trt)-OH, Fmoc-Met-OH, Fmoc-Ala-

OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Val-OH, ~~F~~ Fmoc

~~moc~~-Asn (Trt)-OH, Fmoc-Leu-OH, Fmoc-Ala-OH,

Fmoc-Asp (Ot-Bu)-OH, Fmoc-Tyr (t-Bu)-OH, ~~Fmo~~ Fmoc

~~c~~-Val-OH, Fmoc-Arg (Pmc)-OH, Fmoc-Arg (Pmc)-

OH, Fmoc-Arg (Pmc)-OH, Fmoc-Ile-OH, Fmoc-Asn

(Trt)-OH, Fmoc-Lys (Boc)-OH, Fmoc-Gln (Trt)-

OH, Fmoc-Asp (Ot-Bu)-OH, Fmoc-Tyr (t-Bu)-OH,

Fmoc-Ala-OH, Fmoc-Ser (t-Bu)-OH, Fmoc-Glu ~~(O~~ (Ot-Bu)

~~t-Bu)~~-OH, and Fmoc-Asn (Trt)-OH.

Please amend the paragraphs at page 37, lines 8-20 to read as follows.

Example 4

Synthesis of Compound Ib-2

(CH<sub>3</sub> -CO-Ile-Arg-Arg-Arg-Val-Tyr-Asp-Ala-~~Le~~ Leu  
α-Asn-Val-Leu-Met-Ala-Met-NH<sub>2</sub>, SEQ ID No.4)

In the same manner as in Example 1, a carrier resin (30 mg) bonded with 14.7 .mu.mol of Fmoc-NH as a starting material was condensed sequentially with Fmoc-Met-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc -Leu-OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, ~~Fmo~~ Fmoc c-Leu-OH, Fmoc-Ala-OH, Fmoc-Asp(Ot-Bu)-OH, Fmoc-Tyr (t-Bu)-OH, Fmoc-Val-OH, ~~Fmoc-Arg(P~~ Fmoc-Arg(P- mc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)-OH, and Fmoc-Ile-OH.

Please amend the paragraphs at page 38, lines 12-17 to read as follows.

Example 5

Synthesis of Compound Ic-1

(CH<sub>3</sub> -CO-Ala-Arg-Gly-Arg-Gly-Arg-His-Pro-~~Gl~~ Gly  
γ-Lys-Gly-Val-Lys-Ser-Pro-Gly-Glu-Arg-~~Se~~ Ser  
r-Arg-Tyr-Glu-Thr-Ser-Leu-Asn-Leu-Thr-~~Th~~ Thr  
r-Lys-Arg-Phe-Leu-Glu-Leu-NH<sub>2</sub>, SEQ ID No.5)

Fmoc-Leu-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-Leu-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Gly-OH, Fmoc-Pro-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Val-OH, Fmoc-Gly-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Pro-OH, Fmoc-His(Trt)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Ala-OH.

### Example 6

[CH<sub>3</sub> -(CH<sub>2</sub>)<sub>10</sub> -CO-Leu-Asn-Trp-Ala-Ala-Glu-Val-† L-  
eu Ile-Lys-Val-Gln-Lys-Arg-Arg-Ile-Tyr-Asp-† Ile  
†e-Thr-Asn-Val-Leu-Glu-Gly-Ile-Gln-Leu-† Ile  
†e-Ala-NH<sub>2</sub>, SEQ ID No.20].

Please amend the paragraph starting at page 41, line 25 and ending at page 42, line 8 to read as follows.

Fmoc-Leu-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ile-OH,  
Fmoc-Gly-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Leu-  
OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr  
(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Asp(Ot-Bu)-OH,  
Fmoc-Tyr(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Arg(~~P~~(Pmc)  
~~mc~~)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Lys(Boc)-OH,  
Fmoc-Gln(Trt)-OH, Fmoc-Val-OH, Fmoc-Lys(~~Bo~~ (Boc)  
~~c~~)-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc-Glu(~~Θ~~ (Ot-Bu)  
~~t-Bu~~)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Tr Trp  
p(Boc)-OH, Fmoc-Asn (Trt)-OH, and Fmoc-Leu-~~Θ~~ OH.  
H-

Please amend the paragraphs starting at page 43, line 6, and ending at page 44, line 1 to read as follows.

#### Example 7

##### Synthesis of Compound Ib-3

[CH<sub>3</sub>-(CH<sub>2</sub>)<sub>10</sub>-CO-Asn-Glu-Ser-Ala-Tyr-Asp-Gln-~~t~~ L-  
ys-Asn-Ile-Arg-Arg-Arg-Val-Tyr-Asp-Ala-~~t~~ Leu  
~~eu~~-Asn-Val-Leu-Met-Ala-Met-Asn-Ile-Ile-~~s~~ Ser  
~~er~~-NH<sub>2</sub>, SEQ ID No.21].

In the same manner as in Example 6, a carrier resin (100 mg) bonded with  
20 .mu.mol of Fmoc-NH as a starting material was condensed sequentially with  
Fmoc-Ser(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Ile-~~Θ~~ OH,  
H-, Fmoc-Asn(Trt)-OH, Fmoc-Met-OH, Fmoc-Ala-  
OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Val-OH, F Fmoc

~~moc~~-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Ala-OH,  
 Fmoc-Asp(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, ~~Fmo~~ Fmoc  
~~c~~-Val-OH, Fmoc-Arg(Pmc)-OH, ~~Fmoc-Arg(Pmc)-~~ Fmoc-Arg(Pmc)-OH,  
 OH, Fmoc-Arg(Pmc)-OH, Fmoc-Ile-OH, Fmoc-Asn  
 (Trt)-OH, Fmoc-Lys(Boc)-OH, ~~Fmoc-Gln(Trt)-~~ Fmoc-Gln(Trt)-OH,  
 OH, Fmoc-Asp(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH,  
 Fmoc-Ala-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Glu( $\Theta$  (Ot-Bu)  
~~t-Bu~~)-OH, and Fmoc-Asn(Trt)-OH.